Revenue
No reported data
BELITE BIO, INC (BLTE)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Research & development | $45.4M | $29.9M | $24.8M | $8.9M | $7.4M | $3.7M |
| Operating expenses | $84.2M | $40.0M | $31.7M | $12.8M | $9.8M | $5.7M |
| Operating income | −$84.2M | −$40.0M | −$31.7M | −$12.8M | −$9.8M | −$5.7M |
| EBITDAderived | −$84.0M | −$39.8M | — | — | — | — |
| Net income | −$77.6M | −$36.1M | −$31.6M | −$12.6M | −$9.7M | −$5.8M |
| Basic EPSper diluted share | -$2.31 | -$1.18 | -$1.19 | -$0.63 | -$1.01 | -$0.65 |
| Diluted EPSper diluted share | -$2.31 | -$1.18 | -$1.19 | -$0.63 | -$1.01 | -$0.65 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 18, 2026Form 4 | Scholl Hendrik PeterChief Medical Officer | SellAmerican depositary share · indirect | 96 | $147.11 | $14.1K | 15.0K |
| Jun 18, 2026Form 4 | Scholl Hendrik PeterChief Medical Officer | SellAmerican depositary share · indirect | 1.2K | $146.24 | $175.3K | 15.1K |
| Jun 18, 2026Form 4 | Scholl Hendrik PeterChief Medical Officer | SellAmerican depositary share · indirect | 4.9K | $145.43 | $706.9K | 16.3K |
| Jun 18, 2026Form 4 | Scholl Hendrik PeterChief Medical Officer | SellAmerican depositary share · indirect | 3.7K | $144.66 | $542.2K | 21.2K |
| Jun 18, 2026Form 4 | Scholl Hendrik PeterChief Medical Officer | SellAmerican depositary share · indirect | 96 | $143.90 | $13.8K | 24.9K |